中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2015年
8期
587-590
,共4页
唐美月%石宇%王思亮%吴荣
唐美月%石宇%王思亮%吳榮
당미월%석우%왕사량%오영
放射疗法,调强适形%胰腺肿瘤%替吉奥
放射療法,調彊適形%胰腺腫瘤%替吉奧
방사요법,조강괄형%이선종류%체길오
Radiotherapy,intensity-modulated%Pancreatic neoplasms%S-1
目的 探讨调强放疗联合口服替吉奥化疗治疗局部进展期胰腺癌的疗效及安全性.方法 选取42例局部进展期胰腺癌患者,将患者按随机数字表法分为两组,治疗组21例,给予调强放疗的同时替吉奥40 mg/m2每日2次口服,连服2周休息1周为1个疗程,至放疗结束;对照组21例,给予调强放疗的同时吉西他滨1 000 mg/m2加入0.9％氯化钠100 ml中,30 min内静脉滴注,第1,8,22,29天.调强放疗剂量:50.4 Gy/28次,5次/周,1.8 Gy/次.放疗结束后4周评价近期疗效及不良反应.结果 治疗组和对照组有效率和疾病控制率比较差异无统计学意义[57.1％(12/21)比47.6％(10/21)、85.7％(18/21)比76.2％(16/21),P＞0.05].治疗组中性粒细胞减少和血小板减少发生率明显低于对照组[23.8％(5/21)比57.1％(12/21)、28.6％(6/21)比66.7％(14/21)],差异有统计学意义(P＜0.05);两组贫血、恶心、呕吐、转氨酶升高和疲劳发生率比较差异无统计学意义(P＞0.05).结论 调强放疗联合口服替吉奥化疗治疗局部进展期胰腺癌安全有效,值得临床推广.
目的 探討調彊放療聯閤口服替吉奧化療治療跼部進展期胰腺癌的療效及安全性.方法 選取42例跼部進展期胰腺癌患者,將患者按隨機數字錶法分為兩組,治療組21例,給予調彊放療的同時替吉奧40 mg/m2每日2次口服,連服2週休息1週為1箇療程,至放療結束;對照組21例,給予調彊放療的同時吉西他濱1 000 mg/m2加入0.9％氯化鈉100 ml中,30 min內靜脈滴註,第1,8,22,29天.調彊放療劑量:50.4 Gy/28次,5次/週,1.8 Gy/次.放療結束後4週評價近期療效及不良反應.結果 治療組和對照組有效率和疾病控製率比較差異無統計學意義[57.1％(12/21)比47.6％(10/21)、85.7％(18/21)比76.2％(16/21),P＞0.05].治療組中性粒細胞減少和血小闆減少髮生率明顯低于對照組[23.8％(5/21)比57.1％(12/21)、28.6％(6/21)比66.7％(14/21)],差異有統計學意義(P＜0.05);兩組貧血、噁心、嘔吐、轉氨酶升高和疲勞髮生率比較差異無統計學意義(P＞0.05).結論 調彊放療聯閤口服替吉奧化療治療跼部進展期胰腺癌安全有效,值得臨床推廣.
목적 탐토조강방료연합구복체길오화료치료국부진전기이선암적료효급안전성.방법 선취42례국부진전기이선암환자,장환자안수궤수자표법분위량조,치료조21례,급여조강방료적동시체길오40 mg/m2매일2차구복,련복2주휴식1주위1개료정,지방료결속;대조조21례,급여조강방료적동시길서타빈1 000 mg/m2가입0.9％록화납100 ml중,30 min내정맥적주,제1,8,22,29천.조강방료제량:50.4 Gy/28차,5차/주,1.8 Gy/차.방료결속후4주평개근기료효급불량반응.결과 치료조화대조조유효솔화질병공제솔비교차이무통계학의의[57.1％(12/21)비47.6％(10/21)、85.7％(18/21)비76.2％(16/21),P＞0.05].치료조중성립세포감소화혈소판감소발생솔명현저우대조조[23.8％(5/21)비57.1％(12/21)、28.6％(6/21)비66.7％(14/21)],차이유통계학의의(P＜0.05);량조빈혈、악심、구토、전안매승고화피로발생솔비교차이무통계학의의(P＞0.05).결론 조강방료연합구복체길오화료치료국부진전기이선암안전유효,치득림상추엄.
Objective To investigate the feasibility and efficacy of the intensity modulated radiotherapy (IMRT) with oral S-1 for locally advanced pancreatic cancer.Methods Forty-two patients with locally advanced pancreatic cancer were selected,and the patients were divided into 2 groups by random digits table method with 21 cases each.The patients in treatment group were treated by IMRT combined with oral S-1 40 mg/m2 twice daily from day 1 to day 14 of a 21-d cycle;the patients in control group were treated by IMRT combined with 30 min intravenous infusions of gemcitabine 1 000 mg/m2 on day 1,8,21 and 29.Radiation was concurrently delivered at a dose of 50.4 Gy (1.8 Gy/d,5 times per week,28 fractions).The dose of intensity modulated radiotherapy was 1.8 Gy/time (5 times/week,50.4 Gy/28 times).The recent curative effect and untoward reaction were assessed at the end of radiotherapy after 4 weeks.Results There were no statistical differences in efficient rate and disease control rate between treatment group and control group:57.1％ (12/21) vs.47.6％ (10/21) and 85.7％ (18/21) vs.76.2％ (16/21),P ＞ 0.05.The neutropenia rate and thrombocytopenia rate in treatment were significantly lower than those in control group:23.8％ (5/21) vs.57.1％ (12/21) and 28.6％ (6/21) vs.66.7％ (14/21),and there were statistical differences (P ＜ 0.05).There were no statistical differences in the incidences of anemia,nausea,vomiting,elevated aminotransferase and fatigue (P＞ 0.05).Conclusions The IMRT with oral S-1 for locally advanced pancreatic cancer is safe and effective.It is worthy of clinical promotion.
